Valneva SE (VLA.PA)
EUR 1.83
(2.93%)
EUR 1.83
(2.93%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 44.46 Million EUR | 26.67% |
| 2022 | 35.1 Million EUR | -71.71% |
| 2021 | 124.09 Million EUR | 360.77% |
| 2020 | 26.93 Million EUR | 4.5% |
| 2019 | 25.77 Million EUR | 13.4% |
| 2018 | 22.72 Million EUR | 14.03% |
| 2017 | 19.93 Million EUR | -12.2% |
| 2016 | 22.7 Million EUR | -14.94% |
| 2015 | 26.68 Million EUR | 266.48% |
| 2014 | 7.28 Million EUR | 51.11% |
| 2013 | 4.81 Million EUR | 423.24% |
| 2012 | 921 Thousand EUR | -3.15% |
| 2011 | 951 Thousand EUR | 59.83% |
| 2010 | 595 Thousand EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | -100.0% |
| 2007 | 249 Thousand EUR | 39.11% |
| 2006 | 179 Thousand EUR | -26.03% |
| 2005 | 242 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 48.58 Million EUR | 9.26% |
| 2024 Q2 | 48.86 Million EUR | 0.58% |
| 2023 Q1 | 38.99 Million EUR | 11.1% |
| 2023 Q3 | 38 Million EUR | 13.93% |
| 2023 FY | 44.46 Million EUR | 26.67% |
| 2023 Q4 | 44.46 Million EUR | 17.02% |
| 2023 Q2 | 33.35 Million EUR | -14.48% |
| 2022 Q3 | 96.46 Million EUR | 1.32% |
| 2022 Q4 | 35.1 Million EUR | -63.61% |
| 2022 FY | 35.1 Million EUR | -71.71% |
| 2022 Q1 | 139.72 Million EUR | 12.59% |
| 2022 Q2 | 95.2 Million EUR | -31.87% |
| 2021 Q2 | 125.66 Million EUR | 29.02% |
| 2021 Q4 | 124.09 Million EUR | 0.0% |
| 2021 Q1 | 97.4 Million EUR | 261.64% |
| 2021 FY | 124.09 Million EUR | 360.77% |
| 2020 Q4 | 26.93 Million EUR | -5.15% |
| 2020 Q1 | 28.11 Million EUR | 9.1% |
| 2020 Q2 | 30.49 Million EUR | 8.45% |
| 2020 Q3 | 28.39 Million EUR | -6.89% |
| 2020 FY | 26.93 Million EUR | 4.5% |
| 2019 Q4 | 25.77 Million EUR | -4.5% |
| 2019 FY | 25.77 Million EUR | 13.4% |
| 2019 Q3 | 26.98 Million EUR | 9.75% |
| 2019 Q2 | 24.58 Million EUR | 5.77% |
| 2019 Q1 | 23.24 Million EUR | 2.29% |
| 2018 FY | 22.72 Million EUR | 14.03% |
| 2018 Q1 | 19.25 Million EUR | -3.38% |
| 2018 Q3 | 22.98 Million EUR | 13.75% |
| 2018 Q4 | 22.72 Million EUR | -1.12% |
| 2018 Q2 | 20.2 Million EUR | 4.93% |
| 2017 Q2 | 20.8 Million EUR | 3.29% |
| 2017 Q1 | 20.14 Million EUR | -11.26% |
| 2017 Q4 | 19.93 Million EUR | -14.97% |
| 2017 FY | 19.93 Million EUR | -12.2% |
| 2017 Q3 | 23.44 Million EUR | 12.64% |
| 2016 Q1 | 21.91 Million EUR | -17.9% |
| 2016 Q2 | 24.01 Million EUR | 9.6% |
| 2016 Q3 | 24.75 Million EUR | 3.09% |
| 2016 Q4 | 22.7 Million EUR | -8.29% |
| 2016 FY | 22.7 Million EUR | -14.94% |
| 2015 Q4 | 26.68 Million EUR | -8.98% |
| 2015 FY | 26.68 Million EUR | 266.48% |
| 2015 Q2 | 31.12 Million EUR | 2.66% |
| 2015 Q1 | 30.31 Million EUR | 316.29% |
| 2015 Q3 | 29.32 Million EUR | -5.78% |
| 2014 Q2 | 9.19 Million EUR | 44.33% |
| 2014 FY | 7.28 Million EUR | 51.11% |
| 2014 Q4 | 7.28 Million EUR | -19.08% |
| 2014 Q3 | 8.99 Million EUR | -2.13% |
| 2014 Q1 | 6.37 Million EUR | 32.21% |
| 2013 FY | 4.81 Million EUR | 423.24% |
| 2013 Q1 | - EUR | -100.0% |
| 2013 Q2 | 8.35 Million EUR | 0.0% |
| 2013 Q3 | 6.67 Million EUR | -20.03% |
| 2013 Q4 | 4.81 Million EUR | -27.84% |
| 2012 Q4 | 921 Thousand EUR | 0.0% |
| 2012 Q2 | 902 Thousand EUR | 0.0% |
| 2012 FY | 921 Thousand EUR | -3.15% |
| 2011 FY | 951 Thousand EUR | 59.83% |
| 2011 Q4 | 951 Thousand EUR | 0.0% |
| 2011 Q2 | 737 Thousand EUR | 0.0% |
| 2010 FY | 595 Thousand EUR | 0.0% |
| 2010 Q4 | 595 Thousand EUR | 0.0% |
| 2010 Q2 | 609 Thousand EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | -100.0% |
| 2007 FY | 249 Thousand EUR | 39.11% |
| 2006 FY | 179 Thousand EUR | -26.03% |
| 2005 FY | 242 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -20020.362% |
| ABIVAX Société Anonyme | 1.00 EUR | -4446599900.0% |
| Adocia SA | 272 Thousand EUR | -16247.794% |
| Aelis Farma SA | 53 Thousand EUR | -83798.113% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | -2454.049% |
| genOway Société anonyme | 982.75 Thousand EUR | -4424.646% |
| IntegraGen SA | 311.44 Thousand EUR | -14177.137% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -26910.971% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 4110.802% |
| Plant Advanced Technologies SA | 1.22 Million EUR | -3531.173% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 37411.204% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -48763.736% |
| Valbiotis SA | 1 Million EUR | -4324.482% |
| TheraVet SA | 123.34 Thousand EUR | -35950.98% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -4446599900.0% |
| argenx SE | 281.12 Million EUR | 84.183% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | -3429.048% |
| DBV Technologies S.A. | 1.00 USD | -4446599900.0% |
| Galapagos NV | 73.97 Million EUR | 39.893% |
| Genfit S.A. | 4000.00 EUR | -1111550.0% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -4446599900.0% |
| Innate Pharma S.A. | 1.00 EUR | -4446599900.0% |
| Inventiva S.A. | 417 Thousand EUR | -10563.309% |
| MaaT Pharma SA | 190 Thousand EUR | -23303.158% |
| MedinCell S.A. | -6.71 Million EUR | 762.288% |
| Nanobiotix S.A. | 200 Thousand EUR | -22133.0% |
| Onward Medical N.V. | 936 Thousand EUR | -4650.641% |
| Oryzon Genomics S.A. | 6029.00 EUR | -737435.246% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -34639.063% |
| Pharming Group N.V. | 51.38 Million EUR | 13.461% |
| Poxel S.A. | 2.95 Million EUR | -1404.263% |
| GenSight Biologics S.A. | 1.00 EUR | -4446599900.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 95.687% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -4446599900.0% |